| Prev Close | 9.30 |
| Day Low/High | 9.30 / 9.43 |
| 52 Wk Low/High | 4.30 / 13.66 |
Flexion Therapeutics, Inc. (FLXN)
9.41
0.11
1.20
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 50.32B |
| Market Cap | 467.98M |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Strong Rebound From Covid-19 Meltdown Turns Bargain Hunting Into a Challenge
A now-overbought market leaves few values available among equities.
A Trio of Back-to-Normality Trades Worth Noting
With lockdowns ending and life as we knew it resuming to some extent, these three stocks should benefit.
Here's a Quartet of Small Biotechs That Could Make for Acquisition Targets
Merger activity is picking up this week in the biotechnology sector and these four promising companies would be good buyout candidates.
2 Small Biopharma Stocks That Should Perk Up as Nation Returns to Work
Flexion Therapeutics and BioDelivery Sciences International have promising products that should do well once the fixation on Covid-19 treatments wanes.
Positive Developments for These 3 Biotech Stocks
We review Acadia Pharmaceuticals, The Medicines Company, and Flexion Therapeutics.
Checking In on 2 Small Biotech Names That Had Big Quarters
Stemline Therapeutics and Flexion Therapeutics both saw their shares climb on positive news developments.
Hopeful Signs for These 2 Small Biotech Stocks
Few parts of this biotech space are more frustrating that what I have dubbed 'Tier 3' biotech concerns.
Be Careful in Both Directions, the Market Beast Is Very Ornery Now
This stock market is doing a nice job of making it tough on everyone.
Trading Notes for Select Stocks
Here's my take on a list of stocks I've been watching.
2 Small Biotech Stocks That Insiders Are Buying
Both names looked poised to go higher as soon as sentiment around the small biotech sector improves.
3 Small Biotechs That Came Up Big on Thursday
Portola Pharmaceuticals, Flexion Therapeutics and BioDelivery Sciences delivered nice third-quarter numbers.
Netflix Is Tonight's Big Report: Here's How I Would Play It
This is a battleground stock that has made big moves in both directions on earnings in the past.
Square Continues to See Extreme Pressure
If you are interested in Square longer term be patient and wait for the drama to end.
Biotechs: Adding to Radius Health, Flexion
This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.
A Rash of Biotech News
The April Jobs report showed that 164,000 jobs were created last month. This is nearly 30,000 jobs less than the consensus. Unemployment rates tumbles to 3.9%, the first time under the 4% level in almost two decades. A rash of biotech news hitting t...
Consider These Tier 3 Biotechs
I hope we get a decent size market decline so I can add to some stakes in what I think are already undervalued biotech holdings.
How Trading Notes Can Increase Your Profits
Inertia is your biggest enemy in this market.
You Can't Reason With a Steamroller
The momentum is crushing everything in its way.
Market Strength Is Putting Bids Under Everything
The indices are hitting highs as the market shrugs off yesterday's rotation.
Twitter's Stock Isn't Only One to Nibble on Post-Thanksgiving
I'm looking for some new entries in less-speculative names, but many stocks need a rest at this point.
The Art and Science of Buying Dips
This can produce big gains, but what if the stock keeps dipping?
Stocks on My Radar on This Selling
I'm always excited about the potential for new trades when we have selling like this.
Housing Stocks Will See Demand Boost
The housing market will continue to improve over the next few years due to pent up demand.
Don't Panic About Biotech
Diversification is absolutely critical when investing in this sector.
Playing Biotech After FDA Approval
Small biotech stocks have a number of hurdles around FDA approval. Here is how to play that cycle.
Why Is Flexion Falling, and Other Questions
The first part of Flexion's decline can be attributed to some profit taking.
Flexion Shares Lower After Proposed Stock Offering -- Biotech Movers
The Burlington, Mass.-based firm announced a proposed public offering of 4 million shares. It plans to use part of the net proceeds to fund manufacturing and commercialization of osteoarthritis knee pain treatment Zilretta.
